Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3799 participants.
Also called NCT02298088
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,799 participants
- Sponsor
- Registry
-
NCT02298088
-
- Other papers using this trial's data
- Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial
- Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Argentina, Australia, Brazil, Canada, China, Colombia, New Zealand, Peru, Russia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02298088. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2017-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
- Acronym
- TREAT
- Condition
- Acute ST Segment Elevation Myocardial Infarction
- Condition
- Thrombolysis in Myocardial Infarction Flow
- Intervention (Drug)
- Ticagrelor 180 mg
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Hospital do Coracao
Record details
- Record id
cardio:ct-nct02298088- Content hash
ad9571e2d6d55a9d25003d63640db5926fca6446abc332dca3e9b67e5204cc9f